NCT06229080Completed
Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
The SEGWAY trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of flow diversion to protect non-tumorous liver function using short-acting gelatin sponge particles during Yttrium-90 radioembolization of liver cancer.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 5 Jan 2024
- Start date
- 15 Mar 2023
- Primary completion date
- 20 Jan 2025
- Lead sponsor
- Next Biomedical Co., Ltd.
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06229080
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 15 Mar 2023 to the primary completion date, 20 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For primary liver cancer, patients who have been diagnosed with a malignancy other than the primary liver cancer within 2 years prior to study enrollment
Other illness
- Liver cancer with vascular invasion
Other
- Patients who have undergone biliary-enteric anastomosis
- Patients with an estimated lung dose of 30 Gy or higher on pre-procedure 99mTc-MAA imaging
- Patients with a known contraindication to gelatin use
Who the study is looking for
- Adults aged 19 years or older
- Patients diagnosed with primary or metastatic liver cancer based on histological and/or radiological findings
- Patients determined, following medical, surgical, or multidisciplinary evaluation, to be best treated by radioembolization
- Patients with no history of local treatments (e.g., ablation, chemoembolization) to the same hepatic lobe within the past year
- Child-Pugh class A
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower
- Patients whose treatment area, as determined by planning angiography, includes at least two liver segments
- Patients for whom normal liver tissue constitutes 50% or more of the treatment volume
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.